CSPC Innovation Pharmaceutical Hits Day Low Amid Price Pressure at CNY 25.75

CSPC Innovation Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.03% to touch an intraday low of CNY 25.75. This performance is part of a broader trend, as the company has faced significant challenges over the past year, resulting in a staggering 50.01% decrease in stock value, while the China Shanghai Composite index has risen by 21.22% during the same period. The company's financial metrics reveal ongoing difficulties, including a negative return on equity of -23.92% and a concerning inventory turnover ratio of just 3.51 times. Additionally, CSPC has reported negative net profit for the last ten consecutive quarters, with a recent quarterly loss of CNY 95.43 million, reflecting a 47.33% decline. Despite being classified as a large-cap company with a market capitalization of CNY 43,219 million, CSPC's performance indicators suggest a challenging environment. The stock's high price-to-book ratio of 16.77 further underscores its current valuation concerns. As CSPC Innovation Pharmaceutical Co. navigates these financial hurdles, its recent performance continues to draw attention in the FMCG sector.